|Day Low/High||4.38 / 4.75|
|52 Wk Low/High||1.12 / 6.47|
I continue to be impressed by how this market refuses to embrace negative narratives but that can change fast.
A correction in the shares of the provider of Covid-19 tests appears to be over and a new uptrend is underway.
Opko's BioReference Labs has performed over 4.3 million Covid-19 tests thus far.
Let's review the charts and indicators.
The parent of BioReference Labs is sending some bullish signals amid a nice recent run higher in its shares.
Opko's BioReference Laboratories is on the cutting edge of Covid-19 testing.
JPMorgan downgrades Opko Health to neutral and initiates Berkshire Hathaway with a buy.
Stocks close out the day slightly down, but post gains for 2016.
The market is off its worst levels of the day. Big biotech and biopharma are providing strength today, with Biogen , Gilead Sciences and Mylan all sporting solid gains in a down market. Energy has made a bit of a comeback, but still is down nearly 2...
Markets are projecting a positive open as Brexit-worries have abated.
Solid earnings and the start of some M&A activity may be just what this sector needs to rise.
The FDA found no problems with the drug, but raised questions about its manufacturer.
After weathering a rocky year, the Miami-based pharmaceutical company is awaiting approval for a drug to treat kidney disease.
The bulls can show them around the place.
Jim Cramer answers viewers' Twitter (TWTR) questions from the floor of the New York Stock Exchange.
Along with the networking company's results, we start to get retail earnings.
Dish Network (DISH) spiked on reports the company is discussing a potential merger with T-Mobile (TMUS).
Jim Cramer answers viewers' stock questions sent in on Twitter (TWTR) from the floor of the New York Stock Exchange.
This jerky and chaotic market makes it difficult to focus on individual stock trades.
The dip-buying is good but we need to see stronger momentum and better leadership.